Involvement of Mediator complex in malignancy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 1, 2014, Pages 66-83

  Schiano, Concetta ^a   Casamassimi, Amelia ^b   Rienzo, Monica ^b   de Nigris, Filomena ^b   Sommese, Linda ^b   Napoli, Claudio ^a,b  

^a IRCCS SDN   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Biomarkers; Cancer; Mediator complex; Transcription; Tumorigenesis

Indexed keywords

CYCLIN C; CYCLIN DEPENDENT KINASE 8; MEDIATOR COMPLEX; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING PROTEIN;

BRAIN CANCER; BREAST CANCER; CARCINOGENESIS; CDK19 GENE; CDK8 GENE; COLON CANCER; DOWN REGULATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MED1 GENE; MED12 GENE; MED13 GENE; MED13L GENE; MED14 GENE; MED15 GENE; MED17 GENE; MED19 GENE; MED2 GENE; MED23 GENE; MED28 GENE; MED30 GENE; MED4 GENE; MED5 GENE; MELANOMA; MYELOMA; ONCOGENE; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; REVIEW; STOMACH CANCER; TONGUE CARCINOMA; UPREGULATION; UTERINE CERVIX CANCER; UTERUS SARCOMA;

EUKARYOTA;

BIOMARKERS; CANCER; MEDIATOR COMPLEX; TRANSCRIPTION; TUMORIGENESIS;

CYCLIN C; CYCLIN-DEPENDENT KINASE 8; HUMANS; MEDIATOR COMPLEX; MEDIATOR COMPLEX SUBUNIT 1; NEOPLASMS;

EID: 84890877213     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.12.001     Document Type: Review

References (140)

1. Grünberg S., Hahn S. Structural insights into transcription initiation by RNA polymerase II. Trends Biochem. Sci. Oct 11 2013, 38:603-611.
2. Ansari S.A., Morse R.H. Mechanisms of Mediator complex action in transcriptional activation. Cell. Mol. Life Sci. 2013, 70:2743-2756.
3. Conaway R.C., Conaway J.W. The Mediator complex and transcription elongation. Biochim. Biophys. Acta 2013, 1829:69-75.
4. Casamassimi A., Napoli C. MED complexes and eukaryotic transcription regulation: an overview. Biochimie 2007, 89:1439-1446.
5. Taatjes D.J. The human Mediator complex: a versatile, genomewide regulator of transcription. Trends Biochem. Sci. 2010, 35:315-322.
6. Balamotis M.A., Pennella M.A., Stevens J.L., Wasylyk B., Belmont A.S., Berk A.J. Complexity in transcription control at the activation domain-mediator interface. Sci. Signal. 2009, 2:ra20.
7. Boube M., Joulia L., Cribbs D.L., Bourbon H.M. Evidence for a MED of RNA polymerase II transcriptional regulation conserved from yeast to man. Cell 2002, 110:143-151.
8. Napoli C., Sessa M., Infante T., Casamassimi A. Unraveling framework of the ancestral MED complex in human diseases. Biochimie 2012, 94:579-587.
9. Firestein R., Hahn W.C. Revving the throttle on an oncogene: CDK8 takes the driver seat. Cancer Res. 2009, 69:7899-7901.
10. Paoletti A.C., Parmely T.J., Tomomori-Sato C., Sato S., Zhu D., Conaway R.C., Conaway J.W., Florens L., Washburn M.P. Quantitative proteomic analysis of distinct mammalian MED complexes using normalized spectral abundance factors. Proc. Natl. Acad. Sci. 2006, 103:18928-18933.
11. Larivière L., Seizl M., Cramer P. A structural perspective on Mediator function. Curr. Opin. Cell Biol. 2012, 24:305-313.
12. Robinson P.J., Bushnell D.A., Trnka M.J., Burlingame A.L., Kornberg R.D. Structure of the mediator head module bound to the carboxy-terminal domain of RNA polymerase II. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17931-17935.
13. Soutourina J., Wydau S., Ambroise Y., Boschiero C., Werner M. Direct interaction of RNA polymerase II and mediator required for transcription in vivo. Science 2011, 331:1451-1454.
14. Esnault C., Ghavi-Helm J., Brun S., Soutourina J., Van Berkum N., Boschiero C., Holstege F., Werner M. Mediator-dependent recruitment of TFIIH modules in preinitiation complex. Mol. Cell 2008, 31:337-346.
15. Hoeppner S., Baumli S., Cramer P. Structure of the mediator subunit cyclin C and its implications for CDK8 function. J. Mol. Biol. 2005, 350:833-842.
16. Donner A.J., Ebmeier C.C., Taatjes D.J., Espinosa J.M. CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nat. Struct. Mol. Biol. 2010, 17:194-201.
17. Belakavadi M., Fondell J.D. Cyclin-dependent kinase 8 positively cooperates with Mediator to promote thyroid hormone receptor-dependent transcriptional activation. Mol. Cell. Biol. 2010, 30:2437-2448.
18. Donner A.J., Szostek S., Hoover J.M., Espinosa J.M. CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol. Cell 2007, 27:121-133.
19. Knuesel M.T., Meyer K.D., Bernecky C., Taatjes D.J. The human CDK8 subcomplex is a molecular switch that controls Mediator coactivator function. Genes Dev. 2009, 23:439-451.
20. Sato S., Tomomori-Sato C., Parmely T.J., Florens L., Zybailov B., Swanson S.K., Banks C.A., Jin J., Cai Y., Washburn M.P., Conaway J.W., Conaway R.C. A set of consensus mammalian MED subunits identified by multidimensional protein identification technology. Mol. Cell 2004, 14:685-691.
21. Kagey M.H., Newman J.J., Bilodeau S., Zhan Y., Orlando D.A., van Berkum N.L., Ebmeier C.C., Goossens J., Rahl P.B., Levine S.S., Taatjes D.J., Dekker J., Young R.A. Mediator and cohesin connect gene expression and chromatin architecture. Nature 2010, 467:430-435.
22. Apostolou E., Ferrari F., Walsh R.M., Bar-Nur O., Stadtfeld M., Cheloufi S., Stuart H.T., Polo J.M., Ohsumi T.K., Borowsky M.L., Kharchenko P.V., Park P.J., Hochedlinger K. Genome-wide chromatin interactions of the Nanog locus in pluripotency, differentiation, and reprogramming. Cell Stem Cell 2013, 12:699-712.
23. Krebs A.R., Demmers J., Karmodiya K., Chang N.C., Chang A.C., Tora L. ATAC and Mediator coactivators form a stable complex and regulate a set of non-coding RNA genes. EMBO Rep. 2010, 11:541-547.
24. Huang Y., Li W., Yao X., Lin Q.J., Yin J.W., Liang Y., Heiner M., Tian B., Hui J., Wang G. Mediator complex regulates alternative mRNA processing via the MED23 subunit. Mol. Cell 2012, 45:459-469.
25. Semi K., Matsuda Y., Ohnishi K., Yamada Y. Cellular reprogramming and cancer development. Int. J. Cancer 2013, 15:1240-1248.
26. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4:143-153.
27. Malik S., Roeder R.G. The metazoan MED co-activator complex as an integrative hub for transcriptional regulation. Nat. Rev. Genet. 2010, 11:761-772.
28. Belakavadi M., Fondell J.D. Role of the MED complex in nuclear hormone receptor signaling. Rev. Physiol. Biochem. Pharmacol. 2006, 156:23-43.
29. Zhang X., Krutchinsky A., Fukuda A., Chen W., Yamamura S., Chait B.T., Roeder R.G. MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol. Cell 2005, 19:89-100.
30. Kang Y.K., Guermah M., Yuan C.X., Roeder R.G. The TRAP/mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc. Natl. Acad. Sci. 2002, 99:2642-2647.
31. Zhu Y., Qi C., Jain S., Le Beau M.M., Espinosa R., Atkins G.B., Lazar M.A., Yeldandi A.V., Rao M.S., Reddy J.K. Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc. Natl. Acad. Sci. 1999, 96:10848-10853.
32. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2009, 59:225-249.
33. Cui J., Germer K., Wu T., Wang J., Luo J., Wang S.C., Wang Q., Zhang X. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res. 2012, 72:5625-5634.
34. Hasegawa N., Sumitomo A., Fujita A., Aritome N., Mizuta S., Matsui K., Ishino R., Inoue K., Urahama N., Nose J., Mukohara T., Kamoshida S., Roeder R.G., Ito M. Mediator subunits MED1 and MED24 cooperatively contribute to pubertal mammary gland development and growth of breast carcinoma cells. Mol. Cell. Biol. 2012, 32:1483-1495.
35. Wang Q., Sharma D., Ren Y., Fondell J.D. A coregulatory role for the TRAP Mediator complex in androgen receptor-mediated gene expression. J. Biol. Chem. 2002, 277:42852-42858.
36. Jin F., Claessens F., Fondell J.D. Regulation of androgen receptor-dependent transcription by coactivator MED1 is mediated through a newly discovered non canonical binding motif. J. Biol. Chem. 2012, 6:858-870.
37. Vijayvargia R., May M.S., Fondell J.D. A coregulatory role for the Mediator complex in prostate cancer cell proliferation and gene expression. Cancer Res. 2007, 67:4034-4041.
38. Kim H.J., Roh M.S., Son C.H., Kim A.J., Jee H.J., Song N., Kim M., Seo S.Y., Yoo Y.H., Yun J. Loss of Med1/TRAP220 promotes the invasion and metastasis of human non-small-cell lung cancer cells by modulating the expression of metastasis-related genes. Cancer Lett. 2012, 321:195-202.
39. Gade P., Singh A.K., Roy S.K., Reddy S.P., Kalvakolanu D.V. Down-regulation of the transcriptional Mediator subunit Med1 contributes to the loss of expression of metastasis-associated dapk1 in human cancers and cancer cells. Int. J. Cancer 2009, 125:1566-1574.
40. Ndong Jde L., Jean D., Rousselet N., Frade R. Down-regulation of the expression of RB18A/MED1, a cofactor of transcription, triggers strong tumorigenic phenotype of human melanoma cells. Int. J. Cancer 2009, 124:2597-2606.
41. Kuuselo R., Savinainen K., Sandström S., Autio R., Kallioniemi A. MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer. Int. J. Cancer 2011, 129:2553-2565.
42. Kuuselo R., Savinainen K., Azorsa D.O., Basu G.D., Karhu R., Tuzmen S., Mousses S., Kallioniemi A. Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res. 2007, 67:1943-1949.
43. Lyng H., Lando M., Brovig R.S., Svendsrud D.H., Johansen M., Galteland E., Brustugun O.T., Meza-Zepeda L.A., Myklebost O., Kristensen G.B., Hovig E., Stokke T. GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data. Genome Biol. 2008, 9:R86.
44. Haussler M.R., Haussler C.A., Bartik L., Whitfield G.K., Hsieh J.C., Slater S., Jurutka P.W. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr. Rev. 2008, 66:S98-S112.
45. Rachez C., Lemon B.D., Suldan Z., Bromleigh V., Gamble M., Näär A.M., Erdjument-Bromage H., Tempst P., Freedman L.P. Ligand dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999, 398:824-828.
46. Albrecht P., Ansperger-Rescher B., Schuler A., Zeschnigk M., Gallie B., Lohmann D.R. Spectrum of gross deletions and insertions in the RB1 gene in patients with retinoblastoma and association with phenotypic expression. Hum. Mutat. 2005, 26:437-445.
47. Mitter D., Ullmann R., Muradyan A., Klein-Hitpass L., Kanber D., Ounap K., Kaulisch M., Lohmann D. Genotype-phenotype correlations in patients with retinoblastoma and interstitial 13q deletions. Eur. J. Hum. Genet. 2011, 19:947-958.
48. Luoh S.W. Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells. Cancer Genet. Cytogenet. 2002, 136:43-47.
49. Jiang P., Hu Q., Ito M., Meyer S., Waltz S., Khan S., Roeder R.G., Zhang X. Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation. Proc. Natl. Acad. Sci. 2010, 107:6765-6770.
50. Fullwood M.J., Liu M.H., Pan Y.F., Liu J., Xu H., Mohamed Y.B., Orlov Y.L., Velkov S., Ho A., Mei P.H., Chew E.G., Huang P.Y., Welboren W.J., Han Y., Ooi H.S., Ariyaratne P.N., Vega V.B., Luo Y., Tan P.Y., Choy P.Y., Wansa K.D., Zhao B., Lim K.S., Leow S.C., Yow J.S., Joseph R., Li H., Desai K.V., Thomsen J.S., Lee Y.K., Karuturi R.K., Herve T., Bourque G., Stunnenberg H.G., Ruan X., Cacheux-Rataboul V., Sung W.K., Liu E.T., Wei C.L., Cheung E., Ruan Y. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009, 462:58-64.
51. Prenzel T., Kramer F., Bedi U., Nagarajan S., Beissbarth T., Johnsen S.A. Cohesin is required for expression of the estrogen receptor-alpha (ESR1) gene. Epigenetics Chromatin. 2012, 5:13.
52. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., White T.A., Stojanov P., Van Allen E., Stransky N., Nickerson E., Chae S.S., Boysen G., Auclair D., Onofrio R.C., Park K., Kitabayashi N., MacDonald T.Y., Sheikh K., Vuong T., Guiducci C., Cibulskis K., Sivachenko A., Carter S.L., Saksena G., Voet D., Hussain W.M., Ramos A.H., Winckler W., Redman M.C., Ardlie K., Tewari A.K., Mosquera J.M., Rupp N., Wild P.J., Moch H., Morrissey C., Nelson P.S., Kantoff P.W., Gabriel S.B., Golub T.R., Meyerson M., Lander E.S., Getz G., Rubin M.A., Garraway L.A. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44:685-689.
53. D'Angelo E., Prat J. Uterine sarcomas: a review. Gynecol. Oncol. 2010, 116:131-139.
54. Mäkinen N., Mehine M., Tolvanen J., Kaasinen E., Li Y., Lehtonen H.J., Gentile M., Yan J., Enge M., Taipale M., Aavikko M., Katainen R., Virolainen E., Böhling T., Koski T.A., Launonen V., Sjöberg J., Taipale J., Vahteristo P., Aaltonen L.A. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011, 334:252-255.
55. Mäkinen N., Vahteristo P., Kämpjärvi K., Arola J., Bützow R., Aaltonen L.A. MED12 exon 2 mutations in histopathological uterine leiomyoma variants. Eur. J. Hum. Genet. 2013, 21:1300-1303.
56. Pérot G., Croce S., Ribeiro A., Lagarde P., Velasco V., Neuville A., Coindre J.M., Stoeckle E., Floquet A., MacGrogan G., Chibon F. MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One 2012, 7:e40015.
57. Matsubara A., Sekine S., Yoshida M., Yoshida A., Taniguchi H., Kushima R., Tsuda H., Kanai Y. Prevalence of Med12 mutations in uterine and extrauterine smooth muscle tumors. Histopathology 2013, 62:657-661.
58. Je E.M., Kim M.R., Min K.O., Yoo N.J., Lee S.H. Mutational analysis of Med12 exon 2 in uterine leiomyoma and other common tumors. Int. J. Cancer 2012, 131:E1044-E1047.
59. Firestein R., Bass A.J., Kim S.Y., Dunn I.F., Silver S.J., Guney I., Freed E., Ligon A.H., Vena N., Ogino S., Chheda M.G., Tamayo P., Finn S., Shrestha Y., Boehm J.S., Jain S., Bojarski E., Mermel C., Barretina J., Chan J.A., Baselga J., Tabernero J., Root D.E., Fuchs C.S., Loda M., Shivdasani R.A., Meyerson M., Hahn W.C. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008, 455:547-551.
60. Kim Y.W., Park J., Lee H.J., Lee S.Y., Kim S.J. TGF-b sensitivity is determined by N-linked glycosylation of the type II TGF-b receptor. Biochem. J. 2012, 445:403-411.
61. Huang S., Hölzel M., Knijnenburg T., Schlicker A., Roepman P., McDermott U., Garnett M., Grernrum W., Sun C., Prahallad A., Groenendijk F.H., Mittempergher L., Nijkamp W., Neefjes J., Salazar R., Ten Dijke P., Uramoto H., Tanaka F., Beijersbergen R.L., Wessels L.F., Bernards R. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 2012, 151:937-950.
62. Kämpjärvi K., Mäkinen N., Kilpivaara O., Arola J., Heinonen H.R., Böhm J., Abdel-Wahab O., Lehtonen H.J., Pelttari L.M., Mehine M., Schrewe H., Nevanlinna H., Levine R.L., Hokland P., Böhling T., Mecklin J.P., Bützow R., Aaltonen L.A., Vahteristo P. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. Br. J. Cancer 2012, 107:1761-1765.
63. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
64. Hogg M., Paro S., Keegan L.P., O'Connell M.A. RNA editing by mammalian ADARs. Adv. Genet. 2011, 73:87-120.
65. Paz N., Levanon E.Y., Amariglio N., Heimberger A.B., Ram Z., Constantini S., Barbash Z.S., Adamsky K., Safran M., Hirschberg A., Krupsky M., Ben-Dov I., Cazacu S., Mikkelsen T., Brodie C., Eisenberg E., Rechavi G. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 2007, 17:1586-1595.
66. Dominissini D., Moshitch-Moshkovitz S., Amariglio N., Rechavi G. Adenosine-to-inosine RNA editing meets cancer. Carcinogenesis 2011, 32:1569-1577.
67. Cuny M., Kramar A., Courjal F., Johannsdottir V., Iacopetta B., Fontaine H., Grenier J., Culine S., Theillet C. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 2000, 60:1077-1083.
68. Monni O., Barlund M., Mousses S., Kononen J., Sauter G., Heiskanen M., Paavola P., Avela K., Chen Y., Bittner M.L., Kallioniemi A. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc. Natl. Acad. Sci. 2001, 98:5711-5716.
69. Steeg P.S., Ouatas T., Halverson D., Palmieri D., Salerno M. Metastasis suppressor genes: basic biology and potential clinical use. Clin. Breast Cancer 2003, 4:51-62.
70. Angus S.P., Nevins J.R. A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest. Oncogene 2012, 31:4709-4717.
71. Lee J.E., Kim K., Sacchettini J.C., Smith C.V., Safe S. DRIP150 coactivation of estrogen receptor alpha in ZR-75 breast cancer cells is independent of LXXLL motifs. J. Biol. Chem. 2005, 280:8819-8830.
72. Bolt M.J., Stossi F., Newberg J.Y., Orjalo A., Johansson H.E., Mancini M.A. Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses. Nucleic Acids Res. 2013, 41:4036-4048.
73. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506-520.
74. Kato Y., Habas R., Katsuyama Y., Näär A.M., He X. A component of the ARC/Mediator complex required for TGF beta/Nodal signalling. Nature 2002, 418:641-646.
75. Kim M.J., Park B.J., Kang Y.S., Kim H.J., Park J.H., Kang J.W., Lee S.W., Han J.M., Lee H.W., Kim S. Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat. Genet. 2003, 34:330-336.
76. Iyer N.G., Ozdag H., Caldas C. p300/CBP and cancer. Oncogene 2004, 23:4225-4231.
77. Zhao M., Yang X., Fu Y., Wang H., Ning Y., Yan J., Chen Y.G., Wang G. Mediator MED15 modulates transforming growth factor beta (TGFβ)/Smad signaling and breast cancer cell metastasis. J. Mol. Cell Biol. 2013, 5:57-60.
78. Li L.C., Carroll P.R., Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J. Natl. Cancer Inst. 2005, 97:103-115.
79. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 1998, 72:141-196.
80. Rosenbaum E., Hoque M.O., Cohen Y., Zahurak M., Eisenberger M.A., Epstein J.I., Partin A.W., Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin. Cancer Res. 2005, 11:8321-8325.
81. Ke Y. Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J. Natl. Cancer Inst. 2002, 94:482-490.
82. Zhang H., Jiang H., Wang W., Gong J., Zhang L., Chen Z., Ding Q. Expression of Med19 in bladder cancer tissues and its role on bladder cancer cell growth. Urol. Oncol. 2012, 30:920-927.
83. Wen H., Feng C.C., Ding G.X., Meng D.L., Ding Q., Fang Z.J., Xia G.W., Xu G., Jiang H.W. Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2. Ann. Diagn. Pathol. 2013, 17:259-264.
84. Li L.H., He J., Hua D., Guo Z.J., Gao Q. Lentivirus-mediated inhibition of Med19 suppresses growth of breast cancer cells in vitro. Cancer Chemother. Pharmacol. 2011, 68:207-215.
85. Ji-Fu E., Xing J.J., Hao L.Q., Fu C.G. Suppression of lung cancer metastasis-related protein 1 (LCMR1) inhibits the growth of colorectal cancer cells. Mol. Biol. Rep. 2012, 39:3675-3681.
86. Ding X.F., Huang G.M., Shi Y., Li J.A., Fang X.D. Med19 promotes gastric cancer progression and cellular growth. Gene 2012, 504:262-267.
87. Zou S.W., Ai K.X., Wang Z.G., Yuan Z., Yan J., Zheng Q. The role of Med19 in the proliferation and tumorigenesis of human hepatocellular carcinoma cells. Acta Pharmacol. Sin. 2011, 32:354-360.
88. Sun M., Jiang R., Li J.D., Luo S.L., Gao H.W., Jin C.Y., Shi D.L., Wang C.G., Wang B., Zhang X.Y. MED19 promotes proliferation and tumorigenesis of lung cancer. Mol. Cell. Biochem. 2011, 355:27-33.
89. Chen L., Liang Z., Tian Q., Li C., Ma X., Zhang Y., Yang Z., Wang P., Li Y. Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC. J. Exp. Clin. Cancer Res. 2011, 30:18.
90. Xu L.L., Guo S.L., Ma S.R., Luo Y.A. Mammalian mediator 19 mediates H1299 lung adenocarcinoma cell clone conformation, growth, and metastasis. Asian Pac. J. Cancer Prev. 2012, 13:3695-3700.
91. Wang T., Hao L., Feng Y., Wang G., Qin D., Gu G. Knockdown of MED19 by lentivirus-mediated shRNA in human osteosarcoma cells inhibits cell proliferation by inducing cell cycle arrest in the G0/G1 phase. Oncol. Res. 2011, 19:193-201.
92. Liu Y., Tao X., Fan L., Jia L., Gu C., Feng Y. Knockdown of mediator complex subunit 19 inhibits the growth of ovarian cancer. Mol. Med. Rep. 2012, 6:1050-1056.
93. Li X.H., Fang D.N., Zeng C.M. Knockdown of MED19 by short hairpin RNA-mediated gene silencing inhibits pancreatic cancer cell proliferation. Cancer Biother. Radiopharm. 2011, 26:495-501.
94. Imberg-Kazdan K., Ha S., Greenfield A., Poultney C.S., Bonneau R., Logan S.K., Garabedian M.J. A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells. Genome Res. 2013, 23:581-591.
95. Cui X., Xu D., Lv C., Qu F., He J., Chen M., Liu Y., Gao Y., Che J., Yao Y., Yu H. Suppression of MED19 expression by shRNA induces inhibition of cell proliferation and tumorigenesis in human prostate cancer cells. BMB Rep. 2011, 44:547-552.
96. Zhu L.J., Yan W.X., Chen Z.W., Chen Y., Chen D., Zhang T.H., Liao G.Q. Disruption of mediator complex subunit 19 (Med19) inhibits cell growth and migration in tongue cancer. World J. Surg. Oncol. 2013, 11:116.
97. Yin J.W., Liang Y., Park J.Y., Chen D., Yao X., Xiao Q., Liu Z., Jiang B., Fu Y., Bao M., Huang Y., Liu Y., Yan J., Zhu M.S., Yang Z., Gao P., Tian B., Li D., Wang G. Mediator MED23 plays opposing roles in directing smooth muscle cell and adipocyte differentiation. Genes Dev. 2012, 26:2192-2205.
98. Chang C.H., Scott G.K., Kuo W.L., Xiong X., Suzdaltseva Y., Park J.W., Sayre P., Erny K., Collins C., Gray J.W., Benz C.C. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 1997, 14:1617-1622.
99. Tymms M.J., Ng A.Y., Thomas R.S., Schutte B.C., Zhou J., Eyre H.J., Sutherland G.R., Seth A., Rosenberg M., Papas T., Debouck C., Kola I. A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene 1997, 15:2449-2462.
100. Andreoli J.M., Jang S.I., Chung E., Coticchia C.M., Steinert P.M., Markova N.G. The expression of a novel, epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis. Nucleic Acids Res. 1997, 25:4287-4295.
101. Scott G.K., Daniel J.C., Xiong X., Maki R.A., Kabat D., Benz C.C. Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells. J. Biol. Chem. 1994, 269:19848-19858.
102. Asada S., Choi Y., Yamada M., Wang S.C., Hung M.C., Qin J., Uesugi M. External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proc. Natl. Acad. Sci. 2002, 99:12747-12752.
103. Fitzgerald R.C., Hardwick R., Huntsman D., Carneiro F., Guilford P., Blair V., Chung D.C., Norton J., Ragunath K., Van Krieken J.H., Dwerryhouse S., Caldas C. International Gastric Cancer Linkage Consortium, Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J. Med. Genet. 2010, 47:436-444.
104. Majewski I.J., Kluijt I., Cats A., Scerri T.S., de Jong D., Kluin R.J., Hansford S., Hogervorst F.B., Bosma A.J., Hofland I., Winter M., Huntsman D., Jonkers J., Bahlo M., Bernards R. An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J. Pathol. 2013, 229:621-629.
105. Yang X., Zhao M., Xia M., Liu Y., Yan J., Ji H., Wang G. Selective requirement for Mediator MED23 in Ras-active lung cancer. Proc. Natl. Acad. Sci. 2012, 109:E2813-E2822.
106. Jiang Y., Berk M., Yin H., Powell C.T., Xu Y. KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. Clin. Exp. Metastasis 2005, 22:369-376.
107. Ohta S., Lai E.W., Pang A.L., Brouwers F.M., Chan W.Y., Eisenhofer G., de Krijger R., Ksinantova L., Breza J., Blazicek P., Kvetnansky R., Wesley R.A., Pacak K. Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int. J. Cancer 2005, 114:139-143.
108. Mitchell D.C., Stafford L.J., Li D., Bar-Eli M., Liu M. Transcriptional regulation of KiSS-1 gene expression in metastatic melanoma by specificity protein-1 and its coactivator DRIP-130. Oncogene 2007, 26:1739-1747.
109. Lee M.F., Pan M.H., Chiou Y.S., Cheng A.C., Huang H. Resveratrol modulates MED28 (magicin/EG-1) expression and inhibits epidermal growth factor (EGF)-induced migration in MDA-MB-231 human breast cancer cells. J. Agric. Food Chem. 2011, 59:11853-11861.
110. Yoon N.K., Maresh E.L., Elshimali Y., Li A., Horvath S., Seligson D.B., Chia D., Goodglick L. Elevated MED28 expression predicts poor outcome in women with breast cancer. BMC Cancer 2010, 10:335.
111. Huang C.Y., Chou Y.H., Hsieh N.T., Chen H.H., Lee M.F. MED28 regulates MEK1-dependent cellular migration in human breast cancer cells. J. Cell. Physiol. 2012, 227:3820-3827.
112. Zhang L., Maul R.S., Rao J., Apple S., Seligson D., Sartippour M., Rubio R., Brooks M.N. Expression pattern of the novel gene EG-1 in cancer. Clin. Cancer Res. 2004, 10:3504-3508.
113. Tiedemann R.E., Zhu Y.X., Schmidt J., Shi C.X., Sereduk C., Yin H., Mousses S., Stewart A.K. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res. 2012, 72:757-768.
114. Tsutsui T., Umemura H., Tanaka A., Mizuki F., Hirose Y., Ohkuma Y. Human mediator kinase subunit CDK11 plays a negative role in viral activator VP16-dependent transcriptional regulation. Genes Cells 2008, 13:817-826.
115. Duan Z., Zhang J., Choy E., Harmon D., Liu X., Nielsen P., Mankin H., Gray N.S., Hornicek F.J. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clin. Cancer Res. 2012, 18:4580-4588.
116. Knuesel M.T., Meyer K.D., Donner A.J., Espinosa J.M., Taatjes D.J. The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Mol. Cell. Biol. 2009, 29:650-661.
117. van de Peppel J., Kettelarij N., van Bakel H., Kockelkorn T.T., van Leenen D., Holstege F.C. Mediator expression profiling epistasis reveals a signal transduction pathway with antagonistic submodules and highly specific downstream targets. Mol. Cell 2005, 19:511-522.
118. Westerling T., Kuuluvainen E., Makela T.P. Cdk8 is essential for preimplantation mouse development. Mol. Cell. Biol. 2007, 27:6177-6182.
119. Meyer K.D., Donner A.J., Knuesel M.T., York A.G., Espinosa J.M., Taatjes D.J. Cooperative activity of cdk8 and GCN5L within Mediator directs tandem phosphoacetylation of histone H3. EMBO J. 2008, 27:1447-1457.
120. Poss Z.C., Ebmeier C.C., Taatjes D.J. The Mediator complex and transcription regulation. Crit. Rev. Biochem. Mol. Biol. 2013, 48:575-608.
121. Bernecky C., Grob P., Ebmeier C.C., Nogales E., Taatjes D.J. Molecular architecture of the human Mediator-RNA polymerase II-TFIIF assembly. PLoS Biol. 2011, 9:e1000603.
122. Xu W., Ji J.Y. Dysregulation of CDK8 and Cyclin C in tumorigenesis. J. Genet. Genomics 2011, 38:439-452.
123. Larue L., Delmas V. The WNT/Beta-catenin pathway in melanoma. Front. Biosci. 2006, 11:733-742.
124. Schneider E.V., Böttcher J., Blaesse M., Neumann L., Huber R., Maskos K. The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. J. Mol. Biol. 2011, 412:251-266.
125. Firestein R., Shima K., Nosho K., Irahara N., Baba Y., Bojarski E., Giovannucci E.L., Hahn W.C., Fuchs C.S., Ogino S. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int. J. Cancer 2010, 126:2863-2873.
126. Seo J.O., Han S.I., Lim S.C. Role of CDK8 and beta-catenin in colorectal adenocarcinoma. Oncol. Rep. 2010, 24:285-291.
127. Morris E.J., Ji J.Y., Yang F., Di Stefano L., Herr A., Moon N.S., Kwon E.J., Haigis K.M., Näär A.M., Dyson N.J. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 2008, 455:552-556.
128. Adler A.S., McCleland M.L., Truong T., Lau S., Modrusan Z., Soukup T.M., Roose-Girma M., Blackwood E.M., Firestein R. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res. 2012, 72:2129-2139.
129. Kapoor A., Goldberg M.S., Cumberland L.K., Ratnakumar K., Segura M.F., Emanuel P.O., Menendez S., Vardabasso C., Leroy G., Vidal C.I., Polsky D., Osman I., Garcia B.A., Hernando E., Bernstein E. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 2010, 468:1105-1109.
130. Liu L.X., Liu Z.H., Jiang H.C., Zhang W.H., Qi S.Y., Hu J., Wang X.Q., Wu M. Gene expression profiles of hepatoma cell line HLE. World J. Gastroenterol. 2003, 9:683-687.
131. Liu L.X., Jiang H.C., Liu Z.H., Zhu A.L., Zhou J., Zhang W.H., Wang X.Q., Wu M. Gene expression profiles of hepatoma cell line BEL-7402. Hepatogastroenterology 2003, 50:1496-1501.
132. Galamb O., Sipos F., Molnar B., Szoke D., Spisak S., Tulassay Z. Evaluation of malignant and benign gastric biopsy specimens by mRNA expression profile and multivariate statistical methods. Cytometry B Clin. Cytom. 2007, 72:299-309.
133. Yang S., Jeung H.C., Jeong H.J., Choi Y.H., Kim J.E., Jung J.J., Rha S.Y., Yang W.I., Chung H.C. Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. Genomics 2007, 89:451-459.
134. Bondi J., Husdal A., Bukholm G., Nesland J.M., Bakka A., Bukholm I.R. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J. Clin. Pathol. 2005, 58:509-514.
135. Li H., Lahti J.M., Valentine M., Saito M., Reed S.I., Look A.T., Kidd V.J. Molecular cloning and chromosomal localization of the human cyclin C (CCNC) and cyclin E (CCNE) genes: deletion of the CCNC gene in human tumors. Genomics 1996, 32:253-259.
136. Wang B., Xunsun, Liu J.Y., Yang D., Yang L.L., Kong D.X., Meng X.W. The effect of cell cycle and expression of cyclin B1 and cyclin C protein in hepatocellular carcinoma cell line HepG2 and SMMC-7721 after of silencing β-catenin gene. Hepatogastroenterology 2012, 59:515-518.
137. Ohata N., Ito S., Yoshida A., Kunisada T., Numoto K., Jitsumori Y., Kanzaki H., Ozaki T., Shimizu K., Ouchida M. Highly frequent allelic loss of chromosome 6q16-23 in osteosarcoma: involvement of cyclin C in osteosarcoma. Int. J. Mol. Med. 2006, 18:1153-1158.
138. Schiano C., Rienzo M., Casamassimi A., Napoli C. Gene expression profile of the whole Mediator complex in human osteosarcoma and normal osteoblasts. Med. Oncol. 2013, 30:739.
139. Schneider E.V., Böttcher J., Huber R., Maskos K., Neumann L. Structure-kinetic relationship study of CDK8/CycC specific compounds. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:8081-8086.
140. He S.B., Yuan Y., Wang L., Yu M.J., Zhu Y.B., Zhu X.G. Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells. J. Exp. Clin. Cancer Res. 2011, 30:109.